Who
Garen G. Bohlin
Director
Company insider
Files Form 4 as: Director, Karyopharm Therapeutics; Director, Collegium Pharmaceutical; Director, Tetraphase Pharmaceuticals; Director, Protara Therapeutics; Director, Acusphere; Director, Targanta Therapeutics; COO and Assistant Secretary, Sirtris Pharmaceuticals; Director, Praecis Pharmaceuticals.
In numbers
- Trades disclosed
- 66
- Buys
- 2
- Sells
- 2
- Bought
- $81K
- Sold
- $1.6M
- Companies
- 8
- Companies where not an officer
- 7
- First trade
- 8 Jun 2006
- Last trade
- 21 May 2026
- Last filed
- 26 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 May 2026filed 26 May 2026 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Code A | —15,508 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Code A | —15,508 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | COLL Collegium PharmaceuticalPharmaceuticals | SEC FORM 4 Code A | —8,741 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | COLL Collegium PharmaceuticalPharmaceuticals | SEC FORM 4 Code A | —8,741 at $0.00 | filing |
| 11 May 2026filed 13 May 2026 | COLL Collegium PharmaceuticalPharmaceuticals | SEC FORM 4 Code M | $143K8,700 at $16.49 | filing |
| 11 May 2026filed 13 May 2026 | COLL Collegium PharmaceuticalPharmaceuticals | SEC FORM 4 Sold | $323K8,700 at $37.18 | filing |
| 11 May 2026filed 13 May 2026 | COLL Collegium Pharmaceuticaloption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —8,700 at $0.00 | filing |
| 11 May 2026filed 13 May 2026 | COLL Collegium Pharmaceuticaloption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —8,700 at $0.00 | filing |
| 11 May 2026filed 13 May 2026 | COLL Collegium PharmaceuticalPharmaceuticals | SEC FORM 4 Code M | $143K8,700 at $16.49 | filing |
| 11 May 2026filed 13 May 2026 | COLL Collegium PharmaceuticalPharmaceuticals | SEC FORM 4 Sold | $323K8,700 at $37.18 | filing |
| 28 May 2025filed 29 May 2025 | KPTI Karyopharm Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,600 at $0.00 | filing |
| 15 May 2025filed 19 May 2025 | COLL Collegium PharmaceuticalPharmaceuticals | SEC FORM 4 Code A | —9,791 at $0.00 | filing |
| 29 May 2024filed 30 May 2024 | KPTI Karyopharm Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —69,000 at $0.00 | filing |
| 16 May 2024filed 16 May 2024 | COLL Collegium PharmaceuticalPharmaceuticals | SEC FORM 4 Code A | —7,693 at $0.00 | filing |
| 14 May 2024filed 16 May 2024 | COLL Collegium Pharmaceuticaloption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —28,985 at $0.00 | filing |
| 14 May 2024filed 16 May 2024 | COLL Collegium PharmaceuticalPharmaceuticals | SEC FORM 4 Code M | $166K28,985 at $5.73 | filing |
| 14 May 2024filed 16 May 2024 | COLL Collegium PharmaceuticalPharmaceuticals | SEC FORM 4 Sold | $936K28,985 at $32.30 | filing |
| 12 Sep 2023filed 12 Sep 2023 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Bought | $50K41,140 at $1.22 | filing |
| 24 May 2023filed 25 May 2023 | KPTI Karyopharm Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —34,000 at $0.00 | filing |
| 18 May 2023filed 19 May 2023 | COLL Collegium PharmaceuticalPharmaceuticals | SEC FORM 4 Code A | —9,792 at $0.00 | filing |
News
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Stock Has Consensus Price Target of $48.71COLL · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Garen G. Bohlin; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.